BR112014012590A2 - anticorpos anti-cd98 e métodos de uso dos mesmos - Google Patents

anticorpos anti-cd98 e métodos de uso dos mesmos

Info

Publication number
BR112014012590A2
BR112014012590A2 BR112014012590A BR112014012590A BR112014012590A2 BR 112014012590 A2 BR112014012590 A2 BR 112014012590A2 BR 112014012590 A BR112014012590 A BR 112014012590A BR 112014012590 A BR112014012590 A BR 112014012590A BR 112014012590 A2 BR112014012590 A2 BR 112014012590A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
Prior art date
Application number
BR112014012590A
Other languages
English (en)
Other versions
BR112014012590A8 (pt
Inventor
Thein Htun Van Der Horst Edward
Tran Hoang
Lippincott John
Zachwieja Joseph
Original Assignee
Igenica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenica Inc filed Critical Igenica Inc
Publication of BR112014012590A2 publication Critical patent/BR112014012590A2/pt
Publication of BR112014012590A8 publication Critical patent/BR112014012590A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112014012590A 2011-11-23 2012-11-21 Anticorpos anti-cd98 e métodos de uso dos mesmos BR112014012590A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563443P 2011-11-23 2011-11-23
PCT/US2012/066347 WO2013078377A1 (en) 2011-11-23 2012-11-21 Anti-cd98 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
BR112014012590A2 true BR112014012590A2 (pt) 2017-06-20
BR112014012590A8 BR112014012590A8 (pt) 2017-12-19

Family

ID=47295209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012590A BR112014012590A8 (pt) 2011-11-23 2012-11-21 Anticorpos anti-cd98 e métodos de uso dos mesmos

Country Status (15)

Country Link
EP (1) EP2782935A1 (pt)
JP (1) JP2015501639A (pt)
KR (1) KR20140125351A (pt)
CN (1) CN104302669A (pt)
AU (1) AU2012340623A1 (pt)
BR (1) BR112014012590A8 (pt)
CA (1) CA2856873A1 (pt)
HK (1) HK1202877A1 (pt)
IL (1) IL232755A0 (pt)
MX (1) MX2014006272A (pt)
PH (1) PH12014501164A1 (pt)
RU (1) RU2014124530A (pt)
SG (1) SG11201402619VA (pt)
WO (1) WO2013078377A1 (pt)
ZA (1) ZA201403760B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
WO2014197871A2 (en) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-drug conjugates, compositions and methods of use
US10781259B2 (en) 2013-06-06 2020-09-22 Magenta Therapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
WO2016094566A2 (en) * 2014-12-10 2016-06-16 Genentech, Inc. Blood brain barrier receptor antibodies and methods of use
PT3336185T (pt) * 2015-08-10 2022-01-27 Univ Osaka Anticorpo
CN105385694B (zh) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用
CA3027047A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
BR112018075644A2 (pt) * 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-cd98 e conjugados de anticorpo e fármaco
DK3458479T3 (da) 2016-06-08 2021-02-08 Abbvie Inc Anti-b7-h3-antistoffer og antistof-lægemiddelkonjugater
BR112018075630A2 (pt) * 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112020016005A2 (pt) 2018-02-07 2020-12-15 Regeneron Pharmaceuticals, Inc. Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio
EP3715370A1 (en) * 2019-03-28 2020-09-30 Technische Universität München High affinity anticalins directed against human cd98hc
BR112022020453A2 (pt) * 2020-04-08 2022-11-29 Aliada Therapeutics Inc Anticorpos anti-cd98 e usos dos mesmos
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN117561276A (zh) * 2021-06-02 2024-02-13 华辉安健（北京）生物科技有限公司 抗cd98抗体及其应用
TW202334238A (zh) 2021-11-30 2023-09-01 日商第一三共股份有限公司 蛋白酶分解性遮蔽抗體
CN115772541A (zh) * 2021-12-17 2023-03-10 百奥赛图江苏基因生物技术有限公司 Cd98hc基因人源化非人动物的构建方法及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
WO2003029456A1 (en) 2001-10-01 2003-04-10 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EA025871B9 (ru) 2005-10-07 2017-08-31 Экселиксис, Инк. Ингибиторы mek и способы их применения
TWI390034B (zh) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
CN103038255A (zh) * 2010-03-26 2013-04-10 国立大学法人德岛大学 新抗cd98抗体及其用途

Also Published As

Publication number Publication date
BR112014012590A8 (pt) 2017-12-19
HK1202877A1 (en) 2015-10-09
PH12014501164A1 (en) 2014-10-20
AU2012340623A1 (en) 2014-07-17
CA2856873A1 (en) 2013-05-30
NZ626513A (en) 2017-02-24
ZA201403760B (en) 2017-09-27
EP2782935A1 (en) 2014-10-01
MX2014006272A (es) 2014-10-24
IL232755A0 (en) 2014-07-31
WO2013078377A9 (en) 2013-08-08
CN104302669A (zh) 2015-01-21
RU2014124530A (ru) 2015-12-27
WO2013078377A1 (en) 2013-05-30
KR20140125351A (ko) 2014-10-28
JP2015501639A (ja) 2015-01-19
SG11201402619VA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
BR112014012590A2 (pt) anticorpos anti-cd98 e métodos de uso dos mesmos
CO7020870A2 (es) Anticuerpos anti-htra1 y métodos de uso
BR112014002716A2 (pt) anticorpos anti-poliubiquitina e métodos de uso
BR112013017980A2 (pt) polipeptídeos de imunoglobulina marcado com aldeído e método de uso dos mesmos
BR112014028366A2 (pt) anticorpos anti-ly6e e imunoconjugados e métodos de uso
CL2016001556A1 (es) Anticuerpos anti-cd3 y métodos de uso
CL2014002086A1 (es) Anticuerpos cd47 y métodos de uso los mismos
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
CL2015001266A1 (es) Anticuerpos de antihemaglutinina y métodos de uso.
BR112014018136A2 (pt) anticorpos ou uso e método para determinar
BR112012024120A2 (pt) sarms e método de uso dos mesmos
BRPI1014544A8 (pt) anticorpos anti-il-17f e metodos de uso dos mesmos
BR112014010175A2 (pt) unidades de filtro, componentes e recursos destas e métodos de uso e construção
CO6862148A2 (es) Composiciones transdérmicas de ibuprofeno y métodos de uso de las mismas
BR112013014119A2 (pt) novos moduladores e métodos de uso
BR112014009006A2 (pt) compostos heterocíclicos e métodos de uso dos mesmos
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
CL2015000640A1 (es) Variantes de hppd y métodos de uso
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
CO6801741A2 (es) Derivados c4-monometil triterpenoides y sus métodos de uso
BR112013026410A2 (pt) compostos antimicrobianos e métodos de preparação e uso dos mesmos
CO6870005A2 (es) Composición anti-cgrp y uso de las mismas
BR112013025353A2 (pt) combinações de compostos de inibidores de akt e erlotinibe e métodos de uso
CO6801774A2 (es) Compuestos de benzotiazol y su uso farmacéutico

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: IGENICA BIOTHERAPEUTICS, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.